Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles
Launched by V.K.V. AMERICAN HOSPITAL, ISTANBUL · Nov 3, 2009
Trial Information
Current as of June 08, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI.
- • Embryo transfer performed on day 3
- Exclusion Criteria:
- • Participation in another trial that was being conducted in our unit at the same time.
- • Preimplantation genetic screening cycles.
- • Day 5 embryo transfers.
About V.K.V. American Hospital, Istanbul
V.K.V. American Hospital, located in Istanbul, is a leading healthcare institution recognized for its commitment to advanced medical practices and patient care. As a prominent clinical trial sponsor, the hospital collaborates with pharmaceutical and biotechnology companies to facilitate innovative research and development in diverse therapeutic areas. With a focus on enhancing clinical outcomes, V.K.V. American Hospital leverages its state-of-the-art facilities and a multidisciplinary team of experienced professionals to ensure rigorous study protocols and ethical standards are upheld throughout the research process. The hospital's dedication to excellence in clinical trials contributes to the advancement of medical science and the delivery of cutting-edge treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials